Immunosuppressive therapies, such as multiple sclerosis, are a risk for
people with this condition because they can expose them to a greater
risk of Sars-CoV-2 infection. For these reasons, recommendations from
agencies, patient associations and scientific societies follow one
another quickly so that therapy is guaranteed with good efficacy and
without risk, choosing from the many drugs available in multiple
formulations.